Abstract
Phage display has identified the dodecapeptide YHWYGYTPQNVI (GE11) as a ligand that binds to the epidermal growth factor receptor (EGFR) but does not activate the receptor. Here, we compare the EGFR binding affinities of GE11, EGF, and their polyethyleneimine-polyethyleneglycol (PEI-PEG) conjugates. We found that although GE11 by itself does not exhibit measurable affinity to the EGFR, tethering it to PEI-PEG increases its affinity markedly, and complex formation with polyinosine/cytosine (polyIC) further enhances the affinity to the submicromolar range. PolyIC/PPGE11 has a similar strong antitumor effect against EGFR overexpressing tumors in vitro and in vivo, as polyIC/ polyethyleneimine-polyetheleneglycol-EGF (polyIC/PP-EGF). Absence of EGFR activation, as previously shown by us and easier production of GE11 and GE11 conjugates, confer polyIC/PPGE11 a significant advantage over similar EGF-based polyplexes as a potential therapy of EGFR overexpressing tumors. Copyright © 2012 Wiley Periodicals, Inc.
Cite
CITATION STYLE
Abourbeh, G., Shir, A., Mishani, E., Ogris, M., Rödl, W., Wagner, E., & Levitzki, A. (2012). PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors. IUBMB Life, 64(4), 324–330. https://doi.org/10.1002/iub.1002
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.